Hansoh Pharmaceutical Group Company Ltd
Hansoh Pharmaceutical Group's GHG Emissions Data Preview
In 2024, Hansoh Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Hansoh Pharmaceutical Group has also provided a category-level breakdown for 15 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
b
b
b
b
b
b
a
b
b
b
a
a
a
a
b
b
b
a
a
a
aVerified Sources Behind Hansoh Pharmaceutical Group’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Hansoh Pharmaceutical Group’s data sources below and access millions more through our Disclosure Search.
Insights into Hansoh Pharmaceutical Group's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Hansoh Pharmaceutical Group amounted to 101,390.3 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). b
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Hansoh Pharmaceutical Group increased by 10.07%, suggesting that the company faced challenges in reducing its emissions from its core operations. b
Hansoh Pharmaceutical Group's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Hansoh Pharmaceutical Group's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Hansoh Pharmaceutical Group were 13,163.25 metric tons of CO₂ equivalent (tCO₂e). b
Has Hansoh Pharmaceutical Group reduced its Scope 1 emissions over time?
Since 2021, Hansoh Pharmaceutical Group's Scope 1 emissions have increased by 110.41%, reflecting a rising long-term trend in Scope 1 emissions over time. b c
Compared to the previous year (2023), Hansoh Pharmaceutical Group's Scope 1 emissions increased by 24.81%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. b
What are Hansoh Pharmaceutical Group's Scope 2 emissions?
In 2024, Hansoh Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 88,227.05 tCO₂e without specifying the calculation method. b
Has Hansoh Pharmaceutical Group reduced its Scope 2 emissions over time?
Since 2021, Hansoh Pharmaceutical Group's Scope 2 greenhouse gas (GHG) emissions ( Unspecified Calculation Method) have decreased by 23.99%, reflecting a declining long-term trend in Scope 2 emissions over time. b c
Compared to the previous year (2023), Hansoh Pharmaceutical Group's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Hansoh Pharmaceutical Group 's emissions have plateaued with no significant change in its energy consumption footprint. b
What methodology does Hansoh Pharmaceutical Group use for Scope 2 reporting?
In 2024, Hansoh Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology. b
Hansoh Pharmaceutical Group's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Hansoh Pharmaceutical Group's Value Chain Emissions
In 2024, Hansoh Pharmaceutical Group reported 55,724.79 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. b
The 2024 disclosure of Hansoh Pharmaceutical Group includes a breakdown across 15 of the 15 Scope 3 categories defined by the GHG Protocol, up from 4 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chain b
Hansoh Pharmaceutical Group's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Hansoh Pharmaceutical Group's Scope 3 emissions?
In 2024, Hansoh Pharmaceutical Group reported total Scope 3 emissions of 55,724.79 metric tons of CO₂ equivalent (tCO₂e). b
Approximately 74.69% of these emissions originated from upstream activities such as purchased goods and capital goods, while 25.31% came from downstream activities like product use, distribution, and end-of-life treatment. b
Compared to the previous year (2023), Hansoh Pharmaceutical Group's Scope 3 emissions increased by 298.98%, suggesting that the company faced challenges in reducing emissions across its value chain. b
What categories of Scope 3 emissions does Hansoh Pharmaceutical Group disclose?
In 2024, Hansoh Pharmaceutical Group reported emissions for 15 out of the 15 Scope 3 categories defined by the GHG Protocol. a b
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of Hansoh Pharmaceutical Group's Scope 3 emissions?
In 2024, the largest contributors to Hansoh Pharmaceutical Group's Scope 3 emissions were: a b
- Use of Sold Products (Cat. 11): 12,832.96 tCO₂e (23.03%)
- Purchased Goods and Services (Cat. 1): 11,602.47 tCO₂e (20.82%)
- Waste Generated in Operations (Cat. 5): 10,345.72 tCO₂e (18.57%)
Hansoh Pharmaceutical Group's Scope 3 Emissions by Categories
Insights into Hansoh Pharmaceutical Group’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Hansoh Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 13,163.25 tCO₂e and total revenues of USD 1,830 millions. This translates into an emissions intensity of 7.19 tCO₂e per millions USD. b
Hansoh Pharmaceutical Group's Scope 1 Emissions Intensity Compared to Peers
How does Hansoh Pharmaceutical Group's GHG emissions intensity compare to its peers?
In 2024, Hansoh Pharmaceutical Group reported a Scope 1 emissions intensity of 7.19 tCO₂e per millions USD. Compared to the peer group median of 25.27 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. b
Where does Hansoh Pharmaceutical Group rank on GHG emissions intensity within its industry?
In 2024, Hansoh Pharmaceutical Group ranked 9 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). b
Hansoh Pharmaceutical Group is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. b
Insights into Hansoh Pharmaceutical Group's Total Carbon Footprint
In 2024, Hansoh Pharmaceutical Group reported a total carbon footprint of 157,115.09 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 48.11% increase compared to 2023, suggesting a rise in emissions across its operations or value chain. b
The largest contributor to Hansoh Pharmaceutical Group's total carbon footprint was Scope 2 emissions, accounting for 56.15% of the company's total carbon footprint, followed by Scope 3 emissions at 35.47%. b